Hemostemix Featured at Innovations in Wound Healing 2025, Key West, December 11-14

Rhea-AI Summary

Hemostemix (OTCQB: HMTXF) will present at Innovations in Wound Healing 2025 in Key West, Florida, December 11-14, highlighting clinical data for its cell therapy ACP-01/VesCell in peripheral arterial disease and chronic limb-threatening ischemia (CLTI).

Key disclosed findings include published studies reporting 83% limb salvage, 0% mortality in some cohorts, and reported ulcer size reduction from a mean of 146 mm2 to 0.48 mm2 at 3 months in treated patients. The release notes ACP-01 is available in Florida under SB 1768.

News Market Reaction

-8.90%

1 alert

-8.90% News Effect

On the day this news was published, HMTXF declined 8.90%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Limb salvage rate: 83% Mortality in treated group: 0% Ulcer size reduction: 146 mm2 to 0.48 mm2 +5 more

8 metrics

Limb salvage rate 83% CLTI limb salvage in Mutirangura 2009 and University of Toronto VesCell data

Mortality in treated group 0% University of British Columbia & Toronto poster and VesCell Phase II midpoint

Ulcer size reduction 146 mm2 to 0.48 mm2 Henderson et al. CLTI patients at 3 months after ACP-01

P-value p = 0.01 Ulcer size change in treated CLTI patients vs baseline

Treatment group amputation rate 4.8% Henderson et al. one amputation among treated ACP-01 patients at one year

Placebo amputation rate 25% Henderson et al. amputations in placebo group at one year

Treatment group mortality 4.8% Henderson et al. deaths in ACP-01 treated group at one year

Placebo mortality 12.5% Henderson et al. deaths in placebo group at one year

Market Reality Check

Price: $0.0643 Vol: Volume 22,000 is above th...

high vol

$0.0643 Last Close

Volume Volume 22,000 is above the 20-day average of 14,402 (relative volume 1.53x). high

Technical Price 0.06364 is trading below the 200-day MA at 0.09, despite a 0.95% daily gain.

Peers on Argus

Peers show mixed moves: one biotech peer up 15.96%, another flat, one down 7.63%...

Peers show mixed moves: one biotech peer up 15.96%, another flat, one down 7.63%, and one with an extreme move of 2400%, indicating stock-specific dynamics rather than a unified sector trend.

Historical Context

5 past events · Latest: Dec 03 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 03	Conference feature	Positive	-8.9%	Key West wound-healing meeting highlighting ACP-01/VesCell clinical outcomes and Florida access.
Dec 02	Conference & financing	Positive	-3.2%	DFCon presentation plus closing of a non-brokered private placement with warrants.
Nov 26	Practice acquisitions	Positive	-3.2%	LOI to acquire two cardiology practices and update on unit financing extension.
Nov 18	Conference preview	Positive	+6.6%	Announcement of ACP-01 data at a Florida wound care conference and market sizing.
Nov 13	Academic presentation	Positive	-3.2%	Grand Rounds presentation covering ACP-01 safety, efficacy signals and Florida access pathway.

Pattern Detected

Recent positive operational and clinical announcements have more often been followed by negative price reactions, with only one of the last five news events seeing an aligned positive move.

Recent Company History

This announcement continues a sequence of clinically focused communications. Since November 13, Hemostemix has highlighted ACP-01 data at University of Florida Grand Rounds, emphasized safety and functional gains, and reiterated Florida access. Subsequent releases detailed wound-care conference presentations, market sizing, and a roll-up strategy acquiring two cardiology practices for 2,000,000 shares each. The private placement on December 2 added $518,440 of financing at $0.11 per unit with attached warrants. Today’s conference-focused news reinforces the same ACP-01/VesCell clinical narrative and Florida availability under SB 1768.

Market Pulse Summary

The stock moved -8.9% in the session following this news. A negative reaction despite positive clini...

Analysis

The stock moved -8.9% in the session following this news. A negative reaction despite positive clinical framing would fit a recent pattern where upbeat conference, clinical, and financing updates were followed by selling. The article reiterates previously cited data such as 83% limb salvage and 0% mortality in certain cohorts, plus Florida access under SB 1768, rather than introducing a new pivotal catalyst. With shares trading below the 200-day MA before this release, sentiment may have remained fragile, and some holders might have used the news to exit positions.

Key Terms

chronic limb-threatening ischemia, angiogenesis, perfusion, ischemic, +4 more

8 terms

chronic limb-threatening ischemia medical

"clinical trial results in cardiovascular disease including Chronic Limb-Threatening Ischemia (CLTI)…"

A severe, long-lasting condition in which poor blood flow to the leg or foot causes constant pain, non-healing sores, or gangrene and greatly increases the risk of limb amputation; think of it like a garden plant that can’t get water, so tissue begins to die. It matters to investors because it creates clear demand for medical devices, drugs, wound-care services and procedures, influences healthcare costs and reimbursement, and can drive the commercial and clinical value of treatments and trials in the vascular and wound-care markets.

angiogenesis medical

"Szabo et al. Cytotherapy, 2013 – Showed enhanced angiogenesis and sustained improvement…"

Angiogenesis is the biological process where the body builds new blood vessels, like laying new roads to deliver oxygen and nutrients to tissues. Investors care because many drugs aim to block or encourage this process to treat cancer, eye diseases, or chronic wounds; success or failure in controlling angiogenesis often determines a therapy’s effectiveness, regulatory approval, safety profile, and commercial potential.

perfusion medical

"Demonstrated restoration of perfusion and wound healing in no-option CLTI patients."

Perfusion is the flow of blood through a tissue or organ, delivering oxygen and nutrients and removing waste so cells can function. For investors, perfusion matters because devices, drugs and diagnostics that improve or measure blood flow can change treatment outcomes and market demand—think of it like irrigation for a garden: poor flow harms health, good flow supports recovery and value.

ischemic medical

"sustained improvement in ischemic limb function over two years…"

Ischemic describes a medical condition in which a tissue or organ is damaged because it receives too little blood and oxygen, often due to a blocked or narrowed vessel. For investors, ischemic conditions matter because they drive demand for treatments, diagnostics and medical devices, affect clinical trial outcomes and regulatory decisions, and can influence healthcare spending and company revenue in related sectors — like a garden hose pinched off, starving plants downstream.

limb salvage medical

"Reported significant clinical improvements and limb salvage (83%)."

Limb salvage describes medical treatments and procedures aimed at saving a hand, arm, foot, or leg from amputation by repairing blood flow, infection, or damaged tissue. For investors, it signals demand for surgical tools, wound-care products, and therapies that can reduce long-term disability and costly amputations—think of it as fixing a broken bridge so traffic keeps moving rather than tearing it down. Successful limb salvage can affect health-care spending, device sales, and reimbursement decisions.

regenerative therapeutics medical

"wound care, diabetic limb salvage, and regenerative therapeutics gather to present…"

Regenerative therapeutics are medical treatments designed to repair, replace or regrow damaged tissues and organs by using a patient’s own cells, engineered cells, or supportive materials that act like scaffolding. For investors this matters because these therapies target chronic or previously untreatable conditions, often carrying high development costs, long timelines and the potential for large clinical and commercial upside—similar to rebuilding a bridge rather than repeatedly patching it.

microvascular circulation medical

"ACP-01's ability to regenerate microvascular circulation…"

Microvascular circulation is the network of the smallest blood vessels—capillaries, arterioles and venules—that deliver oxygen and nutrients to tissues and remove waste, like side streets feeding a city’s neighborhoods. For investors, it matters because problems or improvements in this system drive demand for diagnostics, therapies and medical devices, influence patient outcomes and healthcare costs, and can affect regulatory approval and commercial potential for related treatments.

phase II clinical trial medical

"midpoint result in the phase II clinical trial. Unblinded, the 11 of 12 patients…"

A Phase II clinical trial is a mid-stage study in humans that tests whether an experimental drug or treatment actually works and what dose is effective, typically involving dozens to a few hundred patients and often comparing outcomes to a placebo or standard care. For investors, Phase II results are a major inflection point: clear positive data can substantially increase the odds of later regulatory approval and company value, while negative or uncertain results raise development risk and can sharply reduce expectations—like a detailed test drive after basic safety checks.

AI-generated analysis. Not financial advice.

Calgary, Alberta--(Newsfile Corp. - December 3, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce its participation as a premier regenerative medicine company at Innovations in Wound Healing 2025 in Key West, Florida, December 11-14, where global leaders in vascular surgery, wound care, diabetic limb salvage, and regenerative therapeutics gather to present cutting-edge advancements.

Hemostemix will highlight its unprecedented clinical trial results in cardiovascular disease including Chronic Limb-Threatening Ischemia (CLTI)—a field where the standard of care has remained largely unchanged for decades. With four published clinical studies validating ACP-01's ability to regenerate microvascular circulation, Hemostemix stands at the forefront of limb-preservation medicine:

Peer-Reviewed CLTI Clinical Evidence Presented

• Henderson et al. J Biomed Res Environ Sci. 2024 – Demonstrated restoration of perfusion and wound healing in no-option CLTI patients.
• Mutirangura et al. Journal of the Medical Association of Thailand, 2009 – Reported significant clinical improvements and limb salvage (83%).
• University of British Columbia & University of Toronto Clinical Poster Presentation, 2023 – Documented 0% mortality and improved perfusion and functional outcomes in treated CLTI patients (83%).
• Szabo et al. Cytotherapy, 2013 – Showed enhanced angiogenesis and sustained improvement in ischemic limb function over two years: 0% mortality and 70% limb salvage in the treated, verses 20% mortality and 75% limb loss in the normal care group.

Together, these findings underscore a consistent pattern: Hemostemix's ACP-01 regenerates circulation, restores function, and improves quality of life in patients with severe ischemic peripheral arterial disease.

As compared to a 50% mortality rate within five years for no option patients, the University of Toronto published VesCell generated 0% mortality and limb preservation in 83% of subjects followed for 4.5 years as a midpoint result in the phase II clinical trial. Unblinded, the 11 of 12 patients (83%) received VesCell. As published by Henderson, "…looking at only the patients who presented with wound ulcers before administration of ACP-01, (21 treatment, 8 placebo), Ulcer size in the treated group decreased from a mean of 146 mm2 to 0.48 mm2 (p = 0.01) by 3 months (wounds decreased from the size of a wild strawberry to the size of a grain of sand). There was no significant decrease in the size of the ulcers of the placebo group (p < 0.54). At one year there were no complications related to treatment. The treatment group had one amputation (4.8%) and one death (4.8%); the placebo group had 2 amputations (25%) and 1 death (12.5%)."

ACP-01 AVAILABLE NOW IN FLORIDA UNDER SB 1768

With the enactment of Florida SB 1768, ACP-01 is lawfully available today to Floridians suffering from PAD, CLTI, and ischemic vascular disease who are in pain. Patients can access treatment now through fully compliant medical practices in Florida.

The Message: If in Pain, don't Wait for Irreversible Damage

For decades, cardiovascular patients have been told to "wait until things get worse" before receiving meaningful bypass or stent treatments. Unfortunately, this approach too often leads to:

• Loss of circulation
• Loss of exercise capacity
• Unremitting pain
• Loss of independence
• Decline in mental health and overall vitality = loss of quality of life
• Eventual tissue loss and limb loss

"Hemostemix's position is clear," stated Thomas Smeenk, CEO. "There is no logical or medical justification for waiting until PAD causes irreversible ischemic damage. Early restoration of circulation is the rational, humane, and evidence-based approach," Smeenk said.

Treat early. Regenerate. Improve quality of life while it is worth living.

ACP-01 has demonstrated the ability to:

• Increase perfusion
• Improve exercise capacity
• Reduce ischemic pain
• Accelerate wound healing
• Restore functional mobility
• Enhance quality of life

"This is what healthcare is meant to be: timely, regenerative, preventative, and life-enhancing. We are at a tipping point. Patients deserve regenerative options before they lose circulation, mobility, and before they lose hope. VesCell is available now. Our message to attendees is frank: it's time to change the standard of care. Treatment drives better quality of life and less costs for the payors. Smeenk said.

ABOUT HEMOSTEMIX
Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell™ (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in eleven peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 50% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit www.hemostemix.com.

For further information, please contact: Thomas Smeenk, President, CEO EM: tsmeenk@hemostemix.com / PH: 905-580-4170

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to the Phase I clinical trial of ACP-01 as a treatment for Vascular Dementia, and the treatment of pain related to CLTI in Florida and other jurisdictions related to angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia with Angiogenic Cell Precursors (ACP-01) in furtherance of sales of VesCell™ (ACP-01), and the commercialization of ACP-01 via the sale of compassionate treatments under Florida SB 1768. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedarplus.ca. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276808

FAQ

When and where will Hemostemix (HMTXF) present at Innovations in Wound Healing 2025?

Hemostemix will participate in Key West, Florida from December 11–14, 2025.

What clinical outcomes for ACP-01 did Hemostemix highlight for HMTXF investors?

The company highlighted published results including 83% limb salvage, cohorts with 0% mortality, and ulcer size reduction from 146 mm2 to 0.48 mm2 at 3 months in treated patients.

Is ACP-01/VesCell available to patients in Florida under HMTXF news?

Yes; the release states ACP-01 is lawfully available in Florida under SB 1768 through compliant medical practices.

Which published studies did Hemostemix cite when discussing ACP-01 clinical evidence?

The company cited Henderson et al. (2024), Mutirangura et al. (2009), a 2023 University of British Columbia/University of Toronto poster, and Szabo et al. (2013).

What patient benefits did Hemostemix claim ACP-01 can provide?

The release lists increased perfusion, improved exercise capacity, reduced ischemic pain, accelerated wound healing, restored mobility, and enhanced quality of life.

How should investors interpret Hemostemix's presentation at Innovations in Wound Healing 2025 for HMTXF?

The presentation is positioned to showcase clinical evidence for ACP-01 in CLTI and to inform clinicians and investors about its availability in Florida and potential clinical benefits.